Anixa Biosciences, Inc.
ANIX · NASDAQ
Company research
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company headquartered in San Jose, California, focused on the treatment and prevention of cancer through innovative immunotherapy and vaccine platforms. The company's therapeutic portfolio centers on liraltagene autoleucel (lira-cel), a novel chimeric endocrine receptor T-cell (CER-T) therapy — an advanced form of CAR-T technology — being developed in collaboration with Moffitt Cancer Center for the treatment of ovarian cancer. On the vaccine front, Anixa partners with Cleveland Clinic to develop groundbreaking cancer vaccines targeting triple-negative breast cancer and ovarian cancer, as well as a broader pipeline of "retired protein"-based vaccines addressing high-incidence malignancies such as lung, colon, and prostate cancers. Incorporated in 1982 and formerly known as ITUS Corporation, Anixa operates a distinctive business model of collaborating with world-renowned research institutions, and currently trades on the NASDAQ Capital Market with a market capitalization of approximately $97 million.
Research reports
Simply Wall St’s automated valuation report concludes that ANIX is expensive on a price-to-book basis versus both peers and the broader US biotech industry, while noting that analyst 12‑month targets imply more than double the current share price but lack strong statistical consensus, highlighting significant upside potential alongside valuation and execution risk.
Simply Wall St · June 20, 2026Anixa Biosciences (Nasdaq:ANIX) – Stock AnalysisThis fundamental analysis report profiles Anixa as a pre‑revenue oncology biotech with strong financial health but zero trailing revenue, persistent losses, and cash burn, emphasizing its focus on CAR‑T therapy and cancer vaccines while flagging key risks such as small market cap, lack of near-term profitability, and high dependence on successful clinical outcomes.
Investing.com (summarizing H.C. Wainwright) · June 11, 2026H.C. Wainwright reiterates Buy on Anixa stock, $7 targetThis note summarizes H.C. Wainwright’s reiterated Buy rating and 7.00 price target on ANIX following Q2 FY2026 results, citing a net loss of 2.5 million, strong liquidity with 13.7 million in cash and a current ratio of 9.79, and encouraging Phase 1 ovarian cancer CAR‑T survival data with patients living far beyond the expected 3–4‑month median, while acknowledging the stock has fallen 31% over the past year and appears overvalued versus fair value estimates.
BeyondSPX · December 10, 2025Anixa Biosciences: Lean Innovation Meets Oncology Inflection at $4.62 (NASDAQ:ANIX) – ANIX Research ReportThis in‑depth boutique research report frames ANIX as a lean, capital‑disciplined oncology innovator with first‑in‑class CER‑T and preventive vaccine platforms, arguing for asymmetric upside around 2025–2026 clinical and patent catalysts while highlighting major risks including binary Phase 1 outcomes, limited cash runway, heavy reliance on partnerships, intense immuno‑oncology competition, and likely dilution if licensing or data disappoint.